ReviewFrontiers in neurology2025
The contributing role of CCR5 in dementia.
Review in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microglial Ccl4-Ccr5 signaling links systemic inflammation to synaptic loss and memory deficits in chronic kidney disease.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia is a syndrome of impaired brain function in which cognitive functions such as memory, language, attention, direction, and judgment are impaired, affecting or interfering with daily functioning. As dementia becomes more widespread, it is crucial to investigate the underlying mechanisms that contribute to cognitive decline. C-C chemokine receptor 5 (CCR5) has been extensively researched for its role in immune responses and function as a co-receptor in HIV infection. Current research indicates that CCR5, which acts as a regulator of synaptic plasticity, is involved in modulating various forms of learning and memory. Most studies suggest that CCR5 generally has a detrimental effect on diseases associated with dementia. This review seeks to deliver an extensive analysis of CCR5's role in cognitive processes by summarizing existing literature from both animal and human studies. It will cover the involvement of CCR5 in standard learning and memory functions, as well as in various types of dementia. The review will specifically address conditions such as HIV-related neurocognitive impairment (HAND), Alzheimer's disease (AD), stroke, vascular dementia, multiple sclerosis (MS), frontotemporal dementia (FTD), dementia with Lewy bodies (DLB), and Parkinson's disease with dementia (PDD). Based on the fact that CCR5 plays a contributing role in many diseases that cause dementia, this review also proposed CCR5 inhibition as a possible target for alleviating and ameliorating dementia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.